Literature DB >> 23899453

Berberine metabolites exhibit triglyceride-lowering effects via activation of AMP-activated protein kinase in Hep G2 cells.

Shijie Cao1, Yan Zhou, Peixiang Xu, Ying Wang, Jiankun Yan, Wen Bin, Feng Qiu, Ning Kang.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Rhizoma coptidis (Huanglian in Chinese) is commonly used in Chinese folk medicine to treat diarrhea, diabetes, hypertension, hyperlipidemia and tumors. This herb has increasingly gained attention because of its use as a hypolipidemic herb. Berberine (BBR) is the most important constituent of R. coptidis that contribute to the pharmacological efficacy of the herb. AIM OF THE STUDY: Pharmacokinetic studies have indicated that BBR has poor oral bioavailability. Interestingly, several reports show that absorbed BBR is extensively metabolized in rats and humans. We speculate that the BBR metabolites might be responsible for the pharmacological effects. The aim of this study is to examine BBR metabolites for their triglyceride (TG)-lowering activities and the molecular mechanism to clarify BBR genuine effective forms in vivo.
MATERIALS AND METHODS: Four BBR metabolites were examined their TG-lowering effects with a commercial triglyceride assay kit. Real-time PCR and Western blotting were used to confirm genes and proteins of interest, respectively.
RESULTS: Among those BBR metabolites, M2 exhibited the more potential effects on TG-lowering and AMP-activated protein kinase (AMPK) activation in Hep G2 cells as compared with BBR. Moreover, BBR and M2 inhibited gene expressions of acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), glycerol-3-phosphate acyltransferase (GPAT) and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), but motivated gene expression of medium chain acyl-CoA dehydrogenase (mCAD) significantly.
CONCLUSIONS: The results suggested that the TG-lowering effects of BBR and M2 might be partially mediated by the up-regulation of lipolysis gene expressions and down-regulation of lipogenesis gene expressions through activation of the AMPK signaling pathway. BBR and its metabolites might be in vivo active forms of oral doses of BBR, and M2 might be a promising drug candidate against hyperlipidemia.
© 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  AMPK; Berberine; Hyperlipidemia; Metabolites; Triglyceride

Mesh:

Substances:

Year:  2013        PMID: 23899453     DOI: 10.1016/j.jep.2013.07.025

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  13 in total

1.  Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.

Authors:  Shu-Jun Jiang; Hui Dong; Jing-Bin Li; Li-Jun Xu; Xin Zou; Kai-Fu Wang; Fu-Er Lu; Ping Yi
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

2.  Dietary berberine can ameliorate glucose metabolism disorder of Megalobrama amblycephala exposed to a high-carbohydrate diet.

Authors:  Chang He; Xiaoyan Jia; Li Zhang; Fan Gao; Weibo Jiang; Chuang Wen; Cheng Chi; Xiangfei Li; Guangzhen Jiang; Haifeng Mi; Wenbin Liu; Dingdong Zhang
Journal:  Fish Physiol Biochem       Date:  2021-01-26       Impact factor: 2.794

3.  Berberine improves kidney function in diabetic mice via AMPK activation.

Authors:  Long Zhao; Li-Na Sun; Hui-Bin Nie; Xue-Ling Wang; Guang-Ju Guan
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

4.  Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions.

Authors:  Yong-Jik Lee; Yoo-Na Jang; Yoon-Mi Han; Hyun-Min Kim; Jong-Min Jeong; Hong Seog Seo
Journal:  PPAR Res       Date:  2017-03-13       Impact factor: 4.964

Review 5.  Update on the Benefits and Mechanisms of Action of the Bioactive Vegetal Alkaloid Berberine on Lipid Metabolism and Homeostasis.

Authors:  Yanwen Wang; Jeffrey A Zidichouski
Journal:  Cholesterol       Date:  2018-07-02

6.  Effects of a nutraceutical combination of fermented red rice, liposomal berberine, and curcumin on lipid and inflammatory parameters in patients with mild-to-moderate hypercholesterolemia: an 8-week, open-label, single-arm pilot study.

Authors:  Marco Biagi; Piercarlo Minoretti; Marco Bertona; Enzo Emanuele
Journal:  Arch Med Sci Atheroscler Dis       Date:  2018-11-14

7.  Pharmacokinetics and Excretion of Berberine and Its Nine Metabolites in Rats.

Authors:  Xinchi Feng; Kun Wang; Shijie Cao; Liqin Ding; Feng Qiu
Journal:  Front Pharmacol       Date:  2021-01-15       Impact factor: 5.810

8.  Effects and Components of Herb Pair Huanglian-Banxia on Diabetic Gastroparesis by Network Pharmacology.

Authors:  Guoqiang Liang; Lurong Zhang; Guorong Jiang; Xuanyi Chen; Yang Zong; Fei Wang
Journal:  Biomed Res Int       Date:  2021-10-18       Impact factor: 3.411

Review 9.  Berberine as a Potential Anticancer Agent: A Comprehensive Review.

Authors:  Abdur Rauf; Tareq Abu-Izneid; Anees Ahmed Khalil; Muhammad Imran; Zafar Ali Shah; Talha Bin Emran; Saikat Mitra; Zidan Khan; Fahad A Alhumaydhi; Abdullah S M Aljohani; Ishaq Khan; Md Mominur Rahman; Philippe Jeandet; Tanweer Aslam Gondal
Journal:  Molecules       Date:  2021-12-04       Impact factor: 4.411

Review 10.  The Impacts of Herbal Medicines and Natural Products on Regulating the Hepatic Lipid Metabolism.

Authors:  Sha Li; Yu Xu; Wei Guo; Feiyu Chen; Cheng Zhang; Hor Yue Tan; Ning Wang; Yibin Feng
Journal:  Front Pharmacol       Date:  2020-03-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.